After Sarepta announced that its CEO had resigned effective immediately, RBC Capital thinks that a change at the CEO position could enhance the company's interactions with the FDA and increase its credibility with investors. However, the firm adds that the determining factor for the stock will be the data from the company's eteplirsen drug and how the FDa views it. The company said the CEO's departure will not impact the timelines for the drug, and that there are no issues with its data, added RBC, which keeps a Market Perform rating on the shares.